COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

Compass Pathways’ (CMPS) early psilocybin research was published in The Journal of Psychopharmacology this week. The study suggests that both low and high doses of psilocybin are safe to administer in group settings and do not have negative impacts on thought patterns or processing of emotions. 

Compass Pathways - Compassion Navigation Mental Health Pathways logo

PDF of article